Senate Committee Considers Veterans’ Psychedelic Therapy Research Bill
A U.S. Senate committee is currently reviewing a bipartisan legislative proposal aimed at advancing veterans’ psychedelic therapy research by establishing a dedicated office within the Department of Veterans Affairs (VA). The Senate Veterans’ Affairs Committee convened a hearing to discuss the Veterans Health Administration Novel Therapeutics Preparedness Act (S. 4220), which seeks to streamline the development of innovative treatments for serious mental health conditions affecting veterans, as reported by Marijuana Moment.
While VA officials expressed alignment with the bill’s intent to explore novel therapeutics, they testified that the department does not believe a new office is necessary, citing existing internal initiatives. This legislative effort underscores a growing federal interest in the therapeutic potential of psychedelics for conditions such as post-traumatic stress disorder (PTSD), depression, and traumatic brain injury (TBI) among the veteran population, building on earlier coverage of U.S. veterans’ support for medical cannabis access.
The Veterans Health Administration Novel Therapeutics Preparedness Act
The Veterans Health Administration Novel Therapeutics Preparedness Act (S. 4220) is spearheaded by Senator Tim Sheehy (R-MT) and co-sponsored by Senators Tammy Duckworth (D-IL), Ruben Gallego (D-AZ), and John Boozman (R-AR). The bill proposes the creation of a new VA Office of Novel Therapeutics under the Veterans Health Administration (VHA).
Key Provisions of S. 4220:
- Advance the development of innovative treatments, including psychedelic-assisted therapies.
- Assist in reviewing the scheduling status of substances like psilocybin, ibogaine, and MDMA.
- Establish at least one “Center of Excellence” in each VA regional district to develop a national model for the initiative.
- Form a Veteran Advisory Committee comprising veterans, experts, and health professionals to advise on access barriers and safety protocols.
- Mandate coordination with federal agencies including the U.S. Department of Health and Human Services (HHS), Food and Drug Administration (FDA), Centers for Medicaid & Medicare Services (CMS), Department of Defense (DOD), and Drug Enforcement Administration (DEA) on regulatory issues and potential rescheduling actions.
- Require annual reports to Congress on progress, with an initial report on staffing needs and regulatory barriers within 180 days of enactment.
Senator Gallego, a co-sponsor, emphasized the urgency, stating that “emerging therapies like psychedelic assisted therapies are being explored for veterans with PTSD,” and highlighted concerns about veterans seeking unregulated therapies abroad.
VA’s Stance and Existing Initiatives
Despite the legislative push, VA officials voiced reservations about the bill’s necessity. Margarita Devlin, Principal Deputy Under Secretary for Benefits at the VA’s Veterans Benefits Administration, testified that the department has already established an Integrated Project Team (IPT) for psychedelics. This IPT is proactively addressing many functions proposed for the new office, including:
- Informing VHA senior leaders on psychedelic treatments.
- Developing guidance for research and clinical implementation.
- Creating program evaluation infrastructure for data-driven decisions.
- Developing resources for community care and communications for accurate information dissemination.
Devlin stated that the bill’s requirements would “largely duplicate the efforts of the existing IPT” and raise technical concerns regarding duplication of functions and significant staffing requirements without additional funding. Mark A. Koeniger, Acting Assistant Under Secretary for Health for Patient Care Services at VA’s Veterans Health Administration, echoed these concerns, noting the VA’s anticipation of FDA approvals for some psychedelic research and its efforts to prepare for rapid rollout, while seeking to avoid inefficient duplication of activities.
Broader Support and Policy Context
Non-governmental organizations also provided testimony. Brian Dempsey, Government Affairs Director for the Wounded Warrior Project, cited “unacceptably high” suicide rates among veterans, arguing that traditional mental health treatments have not always been effective. He suggested that innovative therapies like psychedelics “may offer new options for a subset of veterans who have exhausted existing treatments.” Joe Chenelly, National Executive Director of AMVETS, expressed support for the bill’s goal of a structured approach to evaluating novel therapies, emphasizing interdisciplinary care and patient safety.
This legislative action follows a broader trend in U.S. policy, including a previous executive order from the Trump administration focused on expanding and expediting research into the therapeutic benefits of psychedelics. Federal health officials have also indicated steps towards “accelerating” therapeutic access to psychedelics for serious mental health conditions. Groups such as Iraq and Afghanistan Veterans of America, Disabled American Veterans, and the Psychedelic Medicine Coalition are supporting S. 4220, highlighting the continued push for innovative solutions in veterans’ psychedelic therapy research and access.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
